Liver transplant patients may soon ditch daily pills for good
NCT ID NCT07634562
First seen Jun 11, 2026 · Last updated Jun 17, 2026 · Updated 1 time
Summary
This early-stage study tests whether a combination of total lymphoid irradiation and anti-thymocyte globulin can train the immune system to accept a new liver without lifelong anti-rejection medication. Twelve adult liver transplant recipients will receive the treatment after their transplant, with the goal of safely stopping immunosuppressive drugs within two years. If successful, this could reduce side effects and improve quality of life for transplant patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Stanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.